{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:34:18Z","timestamp":1790692458249,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Ajinomoto Co., Inc"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Chromatography B"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.jchromb.2020.121981","type":"journal-article","created":{"date-parts":[[2020,1,27]],"date-time":"2020-01-27T11:35:35Z","timestamp":1580124935000},"page":"121981","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation"],"prefix":"10.1016","volume":"1140","author":[{"given":"Yutaka","family":"Matsuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria-Christina","family":"Malinao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Robles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Mendelsohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchromb.2020.121981_b0010","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1002\/anie.201814215","article-title":"AJICAP: Affinity peptide mediated regiodivergent functionalization of native antibodies","volume":"58","author":"Yamada","year":"2019","journal-title":"Angew. Chem., Int. Ed."},{"key":"10.1016\/j.jchromb.2020.121981_b0015","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jcp.28967","article-title":"Potential drug used in the antibody-drug conjugate (ADC) architecture for cancer therapy","volume":"235","author":"Yaghoubi","year":"2020","journal-title":"J. Cell Physiol."},{"key":"10.1016\/j.jchromb.2020.121981_b0020","doi-asserted-by":"crossref","first-page":"5628","DOI":"10.1002\/jcp.27419","article-title":"Antibody\u2013drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes","volume":"234","author":"Abdollahpour-Alitappeh","year":"2019","journal-title":"J Cell Physiol."},{"key":"10.1016\/j.jchromb.2020.121981_b0025","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","article-title":"Antibody-drug conjugates for cancer treatment","volume":"69","author":"Lambert","year":"2018","journal-title":"Annu. Rev. of Med."},{"key":"10.1016\/j.jchromb.2020.121981_b0030","doi-asserted-by":"crossref","first-page":"6437","DOI":"10.1158\/1078-0432.CCR-11-0762","article-title":"Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer","volume":"17","author":"LoRusso","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2020.121981_b0035","doi-asserted-by":"crossref","first-page":"6428","DOI":"10.1158\/1078-0432.CCR-11-0488","article-title":"Brentuximab Vedotin (SGN-35)","volume":"17","author":"Katz","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jchromb.2020.121981_b0040","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/nbt.2289","article-title":"The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma","volume":"30","author":"Senter","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jchromb.2020.121981_b0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.4161\/mabs.26632","article-title":"Methods for site-specific drug conjugation to antibodies","volume":"6","author":"Behrens","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.jchromb.2020.121981_b0050","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/mabs.27022","article-title":"Site-specific antibody drug conjugates for cancer therapy","volume":"6","author":"Panowski","year":"2014","journal-title":"MAbs"},{"key":"10.1016\/j.jchromb.2020.121981_b0055","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/nbt.1480","article-title":"Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index","volume":"26","author":"Junutula","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jchromb.2020.121981_b0060","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.jchromb.2020.121981_b0065","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1002\/cbic.201900178","article-title":"Recent chemical approaches for sitespecific conjugation of native antibodies: technologies toward next-generation antibody\u2212drug conjugates","volume":"20","author":"Yamada","year":"2019","journal-title":"ChemBioChem"},{"key":"10.1016\/j.jchromb.2020.121981_b0070","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer. Res."},{"key":"10.1016\/j.jchromb.2020.121981_b0075","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/19420862.2017.1412025","article-title":"Challenges and new frontiers in analytical characterization of antibody-drug conjugates","volume":"10","author":"Wagh","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.jchromb.2020.121981_b0080","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1110\/ps.051478705","article-title":"Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry","volume":"14","author":"Wang","year":"2005","journal-title":"Protein Sci."},{"key":"10.1016\/j.jchromb.2020.121981_b0085","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1021\/mp5007536","article-title":"Statistics of the distribution of the abundance of molecules with various drug loads in maytansinoid antibody-drug conjugates","volume":"12","author":"Goldmacher","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jchromb.2020.121981_b0090","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1021\/bc5000109","article-title":"Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate","volume":"25","author":"Kim","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.jchromb.2020.121981_b0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14789450.2016.1132167","article-title":"Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates","volume":"13","author":"Beck","year":"2016","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.jchromb.2020.121981_b0100","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/14789450.2019.1578215","volume":"16","author":"Beck","year":"2019","journal-title":"Expert Rev. Proteomics"},{"key":"10.1016\/j.jchromb.2020.121981_b0105","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.2108","article-title":"Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates","volume":"30","author":"Shen","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jchromb.2020.121981_b0110","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jchromb.2014.12.017","article-title":"Characterization of antibody drug conjugate positional isomers at cysteine residues by peptide mapping LC\u2013MS analysis","volume":"981\u2013982","author":"Janin-Bussat","year":"2015","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jchromb.2020.121981_b0115","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1021\/ac504427k","article-title":"Characterization of the N-terminal heterogeneities of monoclonal antibodies using in-gel charge derivatization of alpha-amines and LC-MS\/MS","volume":"87","author":"Ayoub","year":"2015","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.121981_b0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.aca.2016.11.073","article-title":"Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry","volume":"955","author":"Sang","year":"2017","journal-title":"Anal. Chim. Acta"},{"key":"10.1016\/j.jchromb.2020.121981_b0125","doi-asserted-by":"crossref","first-page":"12724","DOI":"10.1021\/acs.analchem.9b02192","article-title":"Comparison of analytical methods for antibody-drug conjugates produced by chemical site-specific conjugation: first-generation AJICAP","volume":"91","author":"Matsuda","year":"2019","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jchromb.2020.121981_b0130","doi-asserted-by":"crossref","first-page":"2647","DOI":"10.1021\/acs.oprd.9b00316","article-title":"Gram-scale antibody-drug conjugate synthesis by site-specific chemical conjugation: AJICAP first generation","volume":"23","author":"Matsuda","year":"2019","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.jchromb.2020.121981_b0135","doi-asserted-by":"crossref","first-page":"20564","DOI":"10.1021\/acsomega.9b02419","article-title":"Good manufacturing practice strategy for antibody-drug conjugate synthesis using site-specific chemical conjugation: AJICAP first generation","volume":"4","author":"Matsuda","year":"2019","journal-title":"ACS Omega"},{"key":"10.1016\/j.jchromb.2020.121981_b0145","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/bc5005262","article-title":"Long-term stabilization of maleimide-thiol conjugates","volume":"26","author":"Fontaine","year":"2015","journal-title":"Bioconjug. Chem."},{"issue":"11","key":"10.1016\/j.jchromb.2020.121981_b0150","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1007\/s13361-019-02296-2","article-title":"A case study to identify the drug conjugation site of a site-specific antibody-drug-conjugate using middle-down mass spectrometry","volume":"30","author":"Hernandez-Alba","year":"2019","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"10.1016\/j.jchromb.2020.121981_b0160","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.aca.2016.03.006","article-title":"Structural characterization of antibody drug conjugate by a combination of intact, middle-up and bottom-up techniques using sheathless capillary electrophoresis \u2013 Tandem mass spectrometry as nanoESI infusion platform and separation method","volume":"918","author":"Said","year":"2016","journal-title":"Anal. Chim. Acta"}],"container-title":["Journal of Chromatography B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219317167?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1570023219317167?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T22:59:31Z","timestamp":1761605971000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1570023219317167"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":29,"alternative-id":["S1570023219317167"],"URL":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.121981","relation":{},"ISSN":["1570-0232"],"issn-type":[{"value":"1570-0232","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation","name":"articletitle","label":"Article Title"},{"value":"Journal of Chromatography B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchromb.2020.121981","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"121981"}}